News
27.11.2021
PMA Insights: Week 43

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
News
24.11.2021
PMA Insights: Week 47 2021

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Articles
22.11.2021
NICE cost effective medicines

When making a decision about the approval of a new product NICE (National Institute for Health and C...

Read more
Articles
17.11.2021
Head of agencies HAG

The Head of Agency Group (HAG) is a recently launched network created by the European Health Technol...

Read more
News
10.11.2021
PMA Insights: Week 45

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Articles
08.11.2021
High cost oncology combination therapy

The use of combination therapy is increasingly becoming the standard of care in oncology as cancers ...

Read more
Articles
03.11.2021
International Horizon Scanning Initiative

The IHSI is an independent legal entity, with representatives from eight member countries.

Read more
Articles
25.10.2021
Hazard ratio and HTA agencies

In oncology, a hazard ratio (HR) is commonly used to estimate the treatment effect for survival endp...

Read more
Articles
20.10.2021
The QALY shortfall

The QALY Shortfall aims to capture and recognise disease severity by assessing the degree of quality...

Read more
News
13.10.2021
PMA Insights: Week 41

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.